Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 7Active not recruiting 3Unknown 1Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 2Biochemical Recurrent Prostate Cancer 1

Interventions

pembrolizumab 195Nivolumab 146Carboplatin 134Specimen Handling 130Magnetic Resonance Spectroscopy 115Cyclophosphamide 109Paclitaxel 106Cisplatin 98Biopsy 97Radiotherapy 90durvalumab 81Dexamethasone 79atezolizumab 73Ipilimumab 62Gemcitabine 62Rituximab 59Doxorubicin 59Lenalidomide 55Docetaxel 55olaparib 52Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 47Oxaliplatin 47Radiosurgery 42Prednisone 42venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Radium-223 × Clear all
NCT04206319 2026-03-16

Radium-223 in Biochemically Recurrent Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
19 enrolled
Genitourinary

Biochemical Recurrent Prostate Cancer

NCT05924672 2026-01-14

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

University of California, San Francisco

Phase 2 Active not recruiting
2 enrolled
Genitourinary

Prostatic Neoplasms

NCT03230734 2024-09-27

RAPSON

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Active not recruiting
70 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡